Loading
LB1410 is an experimental bispecific antibody from L & L Bio, Ningbo, China in phase 2 trials, aimed at PD-1 and TIM-3.
LB1410 is a bispecific antibody developed by L & L Bio, Ningbo, China. Its targets are PD-1 and TIM-3 (the sponsor names PD-1 x TIM3). The sponsor states: Anti-PD-1/TIM3 bispecific antibody intended to block dual immune checkpoint pathways, given in combination with LB4330. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06468358, plans to enrol 194 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.One arm of LB1410 binds PD-1 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LB1410" OR ABSTRACT:"LB1410") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LB1410, not a curated reading list.
Shares A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors, Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.